Amarin Corp (AMRN) Submits sNDA for New Vascepa API Supplier
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Canaccord Genuity Cuts PT on Amarin (AMRN) But Still Sees a Double
December 20, 2012 11:00 AM ESTCanaccord Genuity cut its price target on Amarin Corporation (NASDAQ: AMRN) from $19 to $17, which still offers nearly 100% upside from current levels.
"We continue to expect business development talks to intensify and Vascepa to receive NCE (five-year exclusivity). Our $17 target is based on a... More
